Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Cited by (177)

Items 101–177 of 177

1. Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease
   Farrell, Geoffrey C., Haczeyni, Fahrettin, Chitturi, Shivakumar · 2018 · Advances in Experimental Medicine and Biology
2. Cell Culture Models of Fatty Acid Overload: Problems and Solutions
   Alsabeeh, Nour, Chausse, Bruno, Kakimoto, Pamela A., Kowaltowski, Alicia J., Shirihai, Orian · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
3. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
   Valenti, Luca, Bugianesi, Elisabetta, Pajvani, Utpal, Targher, Giovanni · 2016 · Liver International
4. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
   Huttasch, Maximilian, Roden, Michael, Kahl, Sabine · 2024 · Metabolism
5. Pathophysiology of NASH: perspectives for a targeted treatment
   Marra, Fabio, Lotersztajn, Sophie · 2013 · Current Pharmaceutical Design
6. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
   Fisher, ffolliott M., Kim, MiSung, Doridot, Ludivine, Cunniff, Jeremy C., Parker, Thomas S., Levine, Daniel M., Hellerstein, Marc K., Hudgins, Lisa C., Maratos-Flier, Eleftheria, Herman, Mark A. · 2017 · Molecular Metabolism
7. Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders
   Johnson, Nathan A., Walton, David W., Sachinwalla, Toos, Thompson, Campbell H., Smith, Kate, Ruell, Patricia A., Stannard, Stephen R., George, Jacob · 2008 · Hepatology
8. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
   Alkhouri, Naim, Lawitz, Eric, Noureddin, Mazen, DeFronzo, Ralph, Shulman, Gerald I. · 2020 · Expert Opinion on Investigational Drugs
9. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass
   Knebel, Birgit, Haas, Jutta, Hartwig, Sonja, Jacob, Sylvia, Köllmer, Cornelia, Nitzgen, Ulrike, Muller–Wieland, Dirk, Kotzka, Jorg · 2012 · PLoS ONE
10. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity
    Patterson, Rainey E., Kalavalapalli, Srilaxmi, Williams, Caroline M., Nautiyal, Manisha, Mathew, Justin T., Martinez, Janie, Reinhard, Mary K., McDougall, Danielle J., Rocca, James R., Yost, Richard A. et al. · 2016 · American Journal of Physiology-Endocrinology and Metabolism
11. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
    Feaver, Ryan E., Cole, Banumathi K., Lawson, Mark J., Hoang, Stephen A., Marukian, Svetlana, Blackman, Brett R., Figler, Robert A., Sanyal, Arun J., Wamhoff, Brian R., Dash, Ajit · 2016 · JCI Insight
12. Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver
    Jelenik, Tomas, Kaul, Kirti, Séquaris, Gilles, Flögel, Ulrich, Phielix, Esther, Kotzka, Jörg, Knebel, Birgit, Fahlbusch, Pia, Hörbelt, Tina, Lehr, Stefan et al. · 2017 · Diabetes
13. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
    Ooi, Geraldine J., Meikle, Peter J., Huynh, Kevin, Earnest, Arul, Roberts, Stuart K., Kemp, William, Parker, Benjamin L., Brown, Wendy, Burton, Paul, Watt, Matthew J. · 2021 · Journal of Hepatology
14. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
    Kim, Albert M., Somayaji, Veena R., Dong, Jennifer Q., Rolph, Timothy P., Weng, Yan, Chabot, Jeffrey R., Gropp, Kathryn E., Talukdar, Saswata, Calle, Roberto A. · 2017 · Diabetes, Obesity and Metabolism
15. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
    Jump, Donald B., Lytle, Kelli A., Depner, Christopher M., Tripathy, Sasmita · 2018 · Pharmacology & Therapeutics
16. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
    Juurinen, Leena, Tiikkainen, Mirja, Häkkinen, Anna-Maija, Hakkarainen, Antti, Yki-Järvinen, Hannele · 2007 · American Journal of Physiology-Endocrinology and Metabolism
17. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly
    Gan, Lay, Chitturi, Shivakumar, Farrell, Geoffrey C. · 2011 · Current Gerontology and Geriatrics Research
18. Lipid metabolism in MASLD and MASH: From mechanism to the clinic
    Carli, Fabrizia, Della Pepa, Giuseppe, Sabatini, Silvia, Vidal Puig, Antonio, Gastaldelli, Amalia · 2024 · JHEP Reports
19. Hepatic glucose metabolism in the steatotic liver
    Scoditti, Egeria, Sabatini, Silvia, Carli, Fabrizia, Gastaldelli, Amalia · 2024 · Nature Reviews Gastroenterology & Hepatology
20. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
    Kaufman, Allegra, Abuqayyas, Lubna, Denney, William S., Tillman, Erik J., Rolph, Tim · 2020 · Cell Reports Medicine
21. In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
    Ramos, Maria Jimenez, Bandiera, Lucia, Menolascina, Filippo, Fallowfield, Jonathan Andrew · 2022 · iScience
22. Liver disease in the morbidly obese: A review of 1000 consecutive patients undergoing weight loss surgery
    Subichin, Michael, Clanton, Jesse, Makuszewski, Marta, Bohon, Ashley, Zografakis, John G., Dan, Adrian · 2015 · Surgery for Obesity and Related Diseases
23. How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
    Duarte, Nádia, Coelho, Inês C., Patarrão, Rita S., Almeida, Joana I., Penha-Gonçalves, Carlos, Macedo, M. Paula · 2015 · BioMed Research International
24. Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
    Keating, Shelley E., Sabag, Angelo, Hallsworth, Kate, Hickman, Ingrid J., Macdonald, Graeme A., Stine, Jonathan G., George, Jacob, Johnson, Nathan A. · 2023 · Sports Medicine
25. The genetics of familial combined hyperlipidaemia
    Brouwers, Martijn C. G. J., van Greevenbroek, Marleen M. J., Stehouwer, Coen D. A., de Graaf, Jacqueline, Stalenhoef, Anton F. H. · 2012 · Nature Reviews Endocrinology
26. The role of ChREBP in carbohydrate sensing and NAFLD development
    Régnier, Marion, Carbinatti, Thaïs, Parlati, Lucia, Benhamed, Fadila, Postic, Catherine · 2023 · Nature Reviews Endocrinology
27. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
    Yao, Zemin, Wang, Yuwei · 2012 · Current Opinion in Lipidology
28. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini, Flavia A, Barchetta, Ilaria, Carotti, Simone, Bertoccini, Laura, Baroni, Marco G, Vespasiani-Gentilucci, Umberto, Cavallo, Maria-Gisella, Morini, Sergio · 2017 · World Journal of Gastroenterology
29. Determinants of VLDL-triglycerides production
    Nielsen, Søren, Karpe, Fredrik · 2012 · Current Opinion in Lipidology
30. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice
    Kelly, Daniel M., Nettleship, Joanne E., Akhtar, Samia, Muraleedharan, Vakkat, Sellers, Donna J., Brooke, Jonathan C., McLaren, David S., Channer, Kevin S., Jones, T. Hugh · 2014 · Life Sciences
31. GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
    Parlevliet, Edwin T., Wang, Yanan, Geerling, Janine J., Schröder-Van der Elst, Janny P., Picha, Kristen, O'Neil, Karyn, Stojanovic-Susulic, Vedrana, Ort, Tatiana, Havekes, Louis M., Romijn, Johannes A. et al. · 2012 · PLoS ONE
32. Recent advances in nonalcholic fatty liver disease
    Greenfield, Victoria, Cheung, Onpan, Sanyal, Arun J · 2008 · Current Opinion in Gastroenterology
33. Effects of exercise training on intrahepatic lipid content in humans
    Brouwers, Bram, Hesselink, Matthijs K. C., Schrauwen, Patrick, Schrauwen-Hinderling, Vera B. · 2016 · Diabetologia
34. Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
    Kang, Gideon G., Trevaskis, Natalie L., Murphy, Andrew J., Febbraio, Mark A. · 2023 · iScience
35. The role of hepassocin in the development of non-alcoholic fatty liver disease
    Wu, Hung-Tsung, Lu, Feng-Hwa, Ou, Horng-Yih, Su, Yu-Chu, Hung, Hao-Chang, Wu, Jin-Shang, Yang, Yi-Ching, Wu, Chao-Liang, Chang, Chih-Jen · 2013 · Journal of Hepatology
36. Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis
    Monsénégo, Julia, Mansouri, Abdelhak, Akkaoui, Marie, Lenoir, Véronique, Esnous, Catherine, Fauveau, Véronique, Tavernier, Valentin, Girard, Jean, Prip-Buus, Carina · 2012 · Journal of Hepatology
37. Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis
    Larter, Claire Z, Yeh, Matthew M, Van Rooyen, Derrick M, Brooling, John, Ghatora, Kamaljit, Farrell, Geoffrey C · 2012 · Journal of Gastroenterology and Hepatology
38. Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
    ter Horst, Kasper W., Vatner, Daniel F., Zhang, Dongyan, Cline, Gary W., Ackermans, Mariette T., Nederveen, Aart J., Verheij, Joanne, Demirkiran, Ahmet, van Wagensveld, Bart A., Dallinga-Thie, Geesje M. et al. · 2021 · Diabetes Care
39. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial
    Thomsen, Mads N., Skytte, Mads J., Samkani, Amirsalar, Carl, Martin H., Weber, Philip, Astrup, Arne, Chabanova, Elizaveta, Fenger, Mogens, Frystyk, Jan, Hartmann, Bolette et al. · 2022 · Diabetologia
40. AMP-activated protein kinase α2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids
    Jelenik, Tomas, Rossmeisl, Martin, Kuda, Ondrej, Jilkova, Zuzana Macek, Medrikova, Dasa, Kus, Vladimir, Hensler, Michal, Janovska, Petra, Miksik, Ivan, Baranowski, Marcin et al. · 2010 · Diabetes
41. GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
    Lee, Jinmi, Hong, Seok-Woo, Rhee, Eun-Jung, Lee, Won-Young · 2012 · Diabetes & Metabolism Journal
42. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
    Pierantonelli, Irene, Rychlicki, Chiara, Agostinelli, Laura, Giordano, Debora Maria, Gaggini, Melania, Fraumene, Cristina, Saponaro, Chiara, Manghina, Valeria, Sartini, Loris, Mingarelli, Eleonora et al. · 2017 · Scientific Reports
43. Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications
    Truong, Xuan Trong, Lee, Dae Ho · 2025 · Diabetes & Metabolism Journal
44. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects
    Utzschneider, Kristina M., Bayer-Carter, Jennifer L., Arbuckle, Matthew D., Tidwell, Jaime M., Richards, Todd L., Craft, Suzanne · 2013 · British Journal of Nutrition
45. Salsalate (Salicylate) Uncouples Mitochondria, Improves Glucose Homeostasis, and Reduces Liver Lipids Independent of AMPK-β1
    Smith, Brennan K., Ford, Rebecca J., Desjardins, Eric M., Green, Alex E., Hughes, Meghan C., Houde, Vanessa P., Day, Emily A., Marcinko, Katarina, Crane, Justin D., Mottillo, Emilio P. et al. · 2016 · Diabetes
46. Does the Mediterranean Diet Have Any Effect on Lipid Profile, Central Obesity and Liver Enzymes in Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects? A Systematic Review and Meta-Analysis of Randomized Control Trials
    Del Bo’, Cristian, Perna, Simone, Allehdan, Sabika, Rafique, Ayesha, Saad, Sara, AlGhareeb, Fahad, Rondanelli, Mariangela, Tayyem, Reema F., Marino, Mirko, Martini, Daniela et al. · 2023 · Nutrients
47. A complex role of activin A in non-alcoholic fatty liver disease
    Yndestad, Arne, Haukeland, John Willy, Dahl, Tuva Børresdatter, Bjøro, Kristian, Gladhaug, Ivar Prydz, Berge, Christ, Damås, Jan Kristian, Haaland, Terese, Løberg, Else Marit, Linnestad, Paul et al. · 2009 · The American Journal of Gastroenterology
48. Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome
    Gupte, Anisha A., Sabek, Omaima M., Fraga, Daniel, Minze, Laurie J., Nishimoto, Satoru K., Liu, Joey Z., Afshar, Solmaz, Gaber, Lillian, Lyon, Christopher J., Gaber, A. Osama et al. · 2014 · Endocrinology
49. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels
    Promrat, Kittichai, Longato, Lisa, Wands, Jack R., de la Monte, Suzanne M. · 2011 · Hepatology Research
50. Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation
    Han, Chang Yeob, Ki, Sung Hwan, Kim, Young Woo, Noh, Kyoung, Lee, Da Yeon, Kang, Bomi, Ryu, Jae-Ha, Jeon, Raok, Kim, Eun Hyun, Hwang, Se Jin et al. · 2011 · Antioxidants & Redox Signaling
51. Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver
    Xia, Mingfeng, Chandrasekaran, Preethi, Rong, Shunxing, Fu, Xiaorong, Mitsche, Matthew A. · 2021 · Journal of Lipid Research
52. B Cell-Activating Factor is Associated With the Histological Severity of Nonalcoholic Fatty Liver Disease
    Miyake, Teruki, Abe, Masanori, Tokumoto, Yoshio, Hirooka, Masashi, Furukawa, Shinya, Kumagi, Teru, Hamada, Maho, Kawasaki, Keitarou, Tada, Fujimasa, Ueda, Teruhisa et al. · 2013 · Hepatology International
53. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
    Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y. et al. · 2013 · American Journal of Physiology-Endocrinology and Metabolism
54. Free fatty acids differentially downregulate chemokines in liver sinusoidal endothelial cells: insights into non-alcoholic fatty liver disease
    McMahan, Rachel H., Porsche, Cara E., Edwards, Michael G., Rosen, Hugo R. · 2016 · PLOS ONE
55. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
    Kostrzewski, Tomasz, Snow, Sophie, Battle, Anya Lindström, Peel, Samantha, Ahmad, Zahida, Basak, Jayati, Surakala, Manasa, Bornot, Aurelie, Lindgren, Julia, Ryaboshapkina, Maria et al. · 2021 · Communications Biology
56. A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans
    Charidemou, Evelina, Ashmore, Tom, Li, Xuefei, McNally, Ben D., West, James A., Liggi, Sonia, Harvey, Matthew, Orford, Elise, Griffin, Julian L. · 2019 · JCI Insight
57. Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression
    Azzu, Vian, Vacca, Michele, Kamzolas, Ioannis, Hall, Zoe, Leslie, Jack, Carobbio, Stefania, Virtue, Samuel, Davies, Susan E., Lukasik, Agnes, Dale, Martin et al. · 2021 · Molecular Metabolism
58. 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
    Nasiri, Maryam, Nikolaou, Nikolaos, Parajes, Silvia, Krone, Nils P., Valsamakis, George, Mastorakos, George, Hughes, Beverly, Taylor, Angela, Bujalska, Iwona J., Gathercole, Laura L. et al. · 2015 · Endocrinology
59. Insulin Regulation of Hepatic Lipid Homeostasis
    Uehara, Kahealani, Santoleri, Dominic, Whitlock, Anna E. Garcia, Titchenell, Paul M. · 2023 · Comprehensive Physiology
60. GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
    Liu, Jia, Wang, Guang, Jia, Yumei, Xu, Yuan · 2015 · Diabetes/Metabolism Research and Reviews
61. Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease
    Karl, Martin, Hasselwander, Solveig, Zhou, Yawen, Reifenberg, Gisela, Kim, Yong Ook, Park, Kyoung‐Sook, Ridder, Dirk A., Wang, Xiaoyu, Seidel, Eric, Hövelmeyer, Nadine et al. · 2022 · Hepatology
62. PPP2R5C couples hepatic glucose and lipid homeostasis
    Cheng, Yong-Sheng, Seibert, Oksana, Klöting, Nora, Dietrich, Arne, Straßburger, Katrin, Fernández-Veledo, Sonia, Vendrell, Joan J., Zorzano, Antonio, Blüher, Matthias, Herzig, Stephan et al. · 2015 · PLoS Genetics
63. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Finney, Alexandra C., Das, Sandeep, Kumar, Dhananjay, McKinney, M. Peyton, Cai, Bishuang, Yurdagul, Arif, Rom, Oren · 2023 · Frontiers in Cardiovascular Medicine
64. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
    Poulsen, Marianne K., Nellemann, Birgitte, Stødkilde-Jørgensen, Hans, Pedersen, Steen B., Grønbæk, Henning, Nielsen, Søren · 2016 · The Journal of Clinical Endocrinology & Metabolism
65. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity
    Wijarnpreecha, Karn, Panjawatanan, Panadeekarn, Aby, Elizabeth, Ahmed, Aijaz, Kim, Donghee · 2019 · Maturitas
66. In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions
    Zhu, Zhixian, Zhang, Xiaoxun, Pan, Qiong, Zhang, Liangjun, Chai, Jin · 2023 · Liver Research
67. Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity
    Lytle, Kelli A, Bush, Nikki C, Triay, Jessica M, Kellogg, Todd A, Kendrick, Michael L, Swain, James M, Gathaiya, Nicola W, Hames, Kazanna C, Jensen, Michael D · 2019 · The Journal of Clinical Endocrinology & Metabolism
68. Integrin-Linked Kinase Is Necessary for the Development of Diet-Induced Hepatic Insulin Resistance
    Williams, Ashley S., Trefts, Elijah, Lantier, Louise, Grueter, Carrie A., Bracy, Deanna P., James, Freyja D., Pozzi, Ambra, Zent, Roy, Wasserman, David H. · 2017 · Diabetes
69. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
    Desjardins, Eric M., Wu, Jianhan, Lavoie, Declan C.T., Ahmadi, Elham, Townsend, Logan K., Morrow, Marisa R., Wang, Dongdong, Tsakiridis, Evangelia E., Batchuluun, Battsetseg, Fayyazi, Russta et al. · 2023 · Cell Reports Medicine
70. Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver
    Fu, Xiaorong, Fletcher, Justin A., Deja, Stanisław, Inigo-Vollmer, Melissa, Burgess, Shawn C., Browning, Jeffrey D. · 2023 · Journal of Clinical Investigation
71. Nonalcoholic fatty liver disease and metabolic syndrome in hypopituitary patients
    Nyenwe, Ebenezer A., Williamson-Baddorf, Sarah, Waters, Bradford, Wan, Jim Y., Solomon, Solomon S. · 2009 · The American Journal of the Medical Sciences
72. Increased visceral adipocyte lipolysis--a pathogenic role in nonalcoholic fatty liver disease?
    Thörne, Anders, Löfgren, Patrik, Hoffstedt, Johan · 2010 · The Journal of Clinical Endocrinology & Metabolism
73. Metabolic injury of hepatocytes promotes progression of NAFLD and AALD
    Carvalho-Gontijo, Raquel, Han, Cuijuan, Zhang, Lei, Zhang, Vivian, Hosseini, Mojgan, Mekeel, Kristin, Schnabl, Bernd, Loomba, Rohit, Karin, Michael, Brenner, David A. et al. · 2022 · Seminars in Liver Disease
74. Weight loss in MASLD restores the balance of liver fatty acid sources
    Lambert, Jennifer E., Ramos-Roman, Maria A., Valdez, Maressa J., Browning, Jeffrey D., Rogers, Thomas, Parks, Elizabeth J. · 2025 · Journal of Clinical Investigation
75. Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis
    Rafiei, Hossein, Yeung, Michelle, Kowalski, Sara, Krystal, Gerald, Elisia, Ingrid · 2023 · Frontiers in Pharmacology
76. Contribution of Liver Fat to Weight Loss–Induced Changes in Serum Hepatokines: A Randomized Controlled Trial
    Telgenkamp, Ine, Kusters, Yvo H A M, Schalkwijk, Casper G, Houben, Alfons J H M, Kooi, M Eline, Lindeboom, Lucas, Bons, Judith A P, Schaper, Nicolaas C, Joris, Peter J, Plat, Jogchum et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
77. Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression
    Huang, Zhengxiang, Li, Lili, Dudley, Kevin, Xiao, Lan, Huang, Gary, Subramaniam, V. Nathan, Chen, Chen, Crawford, Ross, Xiao, Yin · 2025 · BME Frontiers